• FDA Approves Stem-cell Trial for ALS Patients at UM

NSI-566/ALS trial principal investigator, Eva Feldman, M.D., Ph.D., is interviewed for this article announcing FDA approval of Neuralstem’s ALS Phase II trial.

View Article

• ALS Stem Cell Trial Expanding to U-M

Neuralstem’s NSI-566/ALS trial expanding to include University of Michigan, in addition to Emory, is the focus of this report on FDA approval of the Phase II trial.

View Article

• FDA Clears U-M Stem Cell Clinical Trial To Recruit ALS Patients

Medical writer Robin Erb continues her NSI-566/ALS trial reporting with an overview of its next phase, Phase II, which is scheduled to include 15 patients and is now approved by the FDA.

View Article

• Neuralstem: A Top Regenerative Medicine Play

An ex-scientist and professional investor and analyst provides a forward-looking overview of Neuralstem’s near-term NSI-566 trials, and reports on the company’s NSI-189/MDD Phase Ib trial currently underway.

View Article

• “ALS Crisis of Conscience At FDA Spells Opportunity For Neuralstem, Brainstorm”

A Seeking Alpha contributor and biologist, working in applied sciences, writes about the recent FDA public hearing on ALS, and clinical progress in the field.

View Article